Send to

Choose Destination
Open Ophthalmol J. 2017 Jun 12;11:107-116. doi: 10.2174/1874364101711010107. eCollection 2017.

Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy.

Author information

Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Jamaica Hospital Medical Center, Queens, New York, USA.
Research Integrity and Compliance Review Office, Colorado State University, Colorado, USA.
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA.
Ocular Inflammation and Uveitis Foundation, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.



The aim was to report the aqueous humor moxifloxacin concentration and proteome profile of an individual with bilateral uveitis-like syndrome with pigment dispersion.


Multiple reactions monitoring mass spectrometry quantified the aqueous concentration of moxifloxacin in the affected individual. Shotgun proteomic analysis performed via liquid chromatography tandem mass spectrometry (LC-MS/MS) defined the protein profile in the affected individual and unaffected control samples.


Moxifloxacin was present at higher than expected levels in aqueous humor 18 days following oral administration. One-third of the proteins were identified by significantly lower spectral counts in the aqueous of the individual with moxifloxacin associated uveitis compared to the unaffected control.


Moxifloxacin was detected in aqueous humor 18 days following the completion of oral administration. These results suggest that moxifloxacin toxicity may be responsible for the uveitis-like syndrome with pigment dispersion syndrome induced by moxifloxacin therapy.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center